Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy

Kubin, Christine J.; Ellman, Tanya M.; Phadke, Varun K; Haynes, Laura J.; Calfee, David P.; Yin, Michael T.

doi:10.1016/j.jinf.2012.01.015

Cited by 134 publications

(126 citation statements)

References 27 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…La frecuencia de nefrotoxicidad observada se encuentra dentro de los rangos ampliamente reportados en la literatura médica (14-60%) 9,10,12,[14][15][16] . Confirmando los hallazgos previamente descritos por Oliveira, y cols.…”

Section: Discussionunclassified

“…No obstante, en la última década, ante el surgimiento y alta tasa de mortalidad en infecciones invasoras causadas por BGN-MR, polimixina B, en monoterapia o en combinación con otros antimicrobianos activos contra BGN-MR, permanece como el principal antimicrobiano usado para agentes de este tipo en nuestro medio 1,7,8 . Históricamente, la falla renal asociada al uso de polimixina B fluctúa entre 14 y 60% [8][9][10][11][12][13] . No obstante, estudios 8 www.sochinf.cl…”

Section: Introductionunclassified

See 1 more Smart Citation

Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015

Osorio

Barreto

Samboni

et al. 2017

Rev. chil. infectol.

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: Introductionunclassified

Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015

Osorio

Barreto

Samboni

et al. 2017

Rev. chil. infectol.

View full text Add to dashboard Cite

“…Polymyxin-associated neurotoxicity may also limit treatment. [68][69][70] The optimal dosing of the polymyxins is still being determined, as accurate pharmacokinetic and pharmacodynamic data have only recently been elucidated. As a result, US.…”

Section: Cre In Patients With Hematologic Malignancies and Haematopoimentioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

2016

View full text Add to dashboard Cite

Carbapenem-resistant Enterobacteriaceae (CRE) are a major global public health concern and pose a serious threat to immunocompromised hosts, particularly patients with hematologic malignancies and solid organ (SOT) and stem cell transplant recipients. In endemic areas, carbapenem-resistant Klebsiella pneumoniae infections occur in 1-18% of SOT recipients, and patients with hematologic malignancies represent 16-24% of all patients with CRE bacteremia. Mortality rates approaching 60% have been reported in these patient populations. Early diagnosis and rapid initiation of targeted therapy is critical in the management of immunocompromised hosts with CRE infections, as recommended empiric regimens are not active against CRE. Therapeutic options are limited by antibiotic-associated toxicities, interactions with immunosuppressive agents, and paucity of antibiotic options currently available. Prevention of CRE infection in these patients requires a multidisciplinary approach involving hospital epidemiology and antimicrobial stewardship. Large, multicenter studies are needed to develop risk-stratification tools to assist in guiding the management of these individuals.

show abstract

“…The dry antibacterial drug development pipeline has led to the revival of the polymyxin class of antibiotics, colistin (i.e., polymyxin E) and polymyxin B, as a last-line defense for treatment of infections caused by multidrug-resistant (MDR) Gram-negative pathogens (2,3). However, the use of polymyxins has largely been limited by nephrotoxicity, the major dose-limiting factor occurring in up to 60% of patients (4)(5)(6). As a result, development of nephroprotective agents is very important for optimizing clinical use of polymyxins.…”

mentioning

confidence: 99%

Lycopene Attenuates Colistin-Induced Nephrotoxicity in Mice via Activation of the Nrf2/HO-1 Pathway

Dai

Tang

Deng

et al. 2015

Antimicrob Agents Chemother

102

View full text Add to dashboard Cite

bNephrotoxicity is the major dose-limiting factor for the clinical use of colistin against multidrug-resistant (MDR) Gram-negative bacteria. This study aimed to investigate the protective effect of lycopene on colistin-induced nephrotoxicity in a mouse model. Fifty mice were randomly divided into 5 groups: the control group (saline solution), the lycopene group (20 mg/kg of body weight/day administered orally), the colistin group (15 mg/kg/day administered intravenously), the colistin (15 mg/kg/day) plus lycopene (5 mg/kg/day) group, and the colistin (15 mg/kg/day) plus lycopene (20 mg/kg/day) group; all mice were treated for 7 days. At 12 h after the last dose, blood was collected for measurements of blood urea nitrogen (BUN) and serum creatinine levels. The kidney tissue samples were obtained for examination of biomarkers of oxidative stress and apoptosis, histopathological assessment, and quantitative reverse transcription-PCR (qRT-PCR) analysis. Colistin treatment significantly increased concentrations of BUN and serum creatinine, tubular apoptosis/necrosis, lipid peroxidation, and heme oxygenase 1 (HO-1) activity, while the treatment decreased the levels of endogenous antioxidant biomarkers glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). Notably, the changes in the levels of all biomarkers were attenuated in the kidneys of mice treated with colistin by lycopene (5 or 20 mg/kg). Lycopene treatment, especially in the colistin plus lycopene (20 mg/kg) group, significantly downregulated the expression of NF-B mRNA (P < 0.01) but upregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and HO-1 mRNA (both P < 0.01) in the kidney compared with the results seen with the colistin group. Our data demonstrated that coadministration of 20 mg/kg/day lycopene can protect against colistin-induced nephrotoxicity in mice. This effect may be attributed to the antioxidative property of lycopene and its ability to activate the Nrf2/HO-1 pathway.

show abstract

Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy

Cited by 134 publications

References 27 publications

Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015

Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

Lycopene Attenuates Colistin-Induced Nephrotoxicity in Mice via Activation of the Nrf2/HO-1 Pathway

Contact Info

Product

Resources

About